Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia

Dumas, P., Villacreces, A., Guitart, A. V., Ali, E. H., Massara, L., Mansier, O., Bidet, A., Martineau, D., Fernandez, S., Leguay, T., Pigneux, A., Vigon, I., Pasquet, J. and Desplat, V.
Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia.  Clinical Cancer Research. August 16 2021.  doi: 10.1158/1078-0432.ccr-20-3114